Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis
NCT ID: NCT05383521
Last Updated: 2024-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2025-12-01
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis
NCT00324142
Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis
NCT03099408
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
NCT00153517
Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin
NCT03211156
A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects
NCT02585440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
Tinidazole , 1g three times daily for 14 days. At the same time, metronidazole, 400 mg, daily, vaginal administration for 14 days.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tinidazole 56
Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Tinidazole 42
Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Tinidazole 42
Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Tinidazole 56
Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tinidazole 56
Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Tinidazole 42
Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failure of conventional treatment (recommended by guidelines including tinidazole, 2g once daily for 5-7 days)
Exclusion Criteria
* Pregnant or nursing
* HIV or other chronic disease
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shangrong Fan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shangrong Fan
Profesor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shangrong Fan Fan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Peking University Shenzhen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Beijing Obstetrics and Gynecology Hospital,Capital Medical University
Beijing, , China
Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University
Beijing, , China
Peking University First Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhaohui Liu, M.D.
Role: primary
Qinping Liao, M.D.
Role: primary
Dai Zhang, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020PUSZH001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.